A decent start to 2024; guidance unchanged
30/04/24 -"Qiagen started 2024 on a decent note with the operating performance in line with the street’s expectations but above the management’s guidance. As the 2024 sales guidance remained unchanged, a ..."
Pages
64
Language
English
Published on
30/04/24
You may also be interested by these reports :
16/05/24
On the back of the promising beginning to 2024, which was a combination of 1/ normalising market demand in Europe (the lynchpin geography); 2/ the ...
16/05/24
As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from ...
15/05/24
Bastide reported stronger organic growth in Q3 than in the previous two quarters. The group is currently spinning off two Swiss subsidiaries, which ...
15/05/24
Orpea published overall good-looking organic revenue in the Q1, primarily led by improvements in the international performance while its activities ...